| Outcome Measures: |
Primary: evaluate the pharmacokinetics of digoxin after a single dose when administered alone and in combination with AZD1656 at steady state, by assessment of AUC and Cmax of digoxin, Serial PK blood samples will be taken on days 4-8 during the treatment periods | Secondary: evaluate the safety of AZD1656 in combination with digoxin by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables (including 7-point glucose), physical examination and adverse events., Safety assessments will be monitored throughout the study, from screening visit until follow up visit.|describe the pharmacokinetics of AZD1656 and its metabolite during concomitant digoxin administration by assessment of AUC(0-24), Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only)., Serial PK blood samples will be taken on days 4-8 during the treatment periods|describe the pharmacokinetics of digoxin when administered alone or in combination with AZD1656 by assessment of tmax and t1/2., Serial PK blood samples will be taken on days 4-8 during the treatment periods
|
